



RCE/HFW
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REQUEST FOR CONTINUED EXAMINATION AND
PETITION FOR EXTENSION OF TIME

Attorney Docket No.: 01017/39555

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is a Request for Continued Examination under 37 C.F.R. §1.114 of the following application:

Application No. : 10/694,579
Filing Date : October 27, 2003
Inventor(s) : Mehta et al.
Title : G-CSF Therapy as an Adjunct to Reperfusion Therapy in
the Treatment of Acute Myocardial Infarction
Art Unit : 1647
Examiner : James Jason Galvez

1. **Submission required under 37 C.F.R. §1.114**

- ☒ Previously submitted
☒ Please enter and consider the amendment(s)/reply under 37 C.F.R.
§1.116 previously filed May 20, 2005
☒ Enclosed
☒ Amendment/Reply
☐ Affidavit(s)/Declaration(s)
☐ Information disclosure statement

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 10, 2005

Lynn L. Janulis, Registration No. 53,066

08/15/2005 MWOLDGE1 00000016 10694579

01 FC:1801 790.00 OP

08/15/2005 MWOLDGE1 00000016 10694579

02 FC:1251 120.00 OP

2. Miscellaneous

- ☒ This is a petition for a 1 -month extension of time.
- ☐ Suspension of action on the above-identified application is requested under C.F.R. § 1.103(c) for a period of _____ months.
(Suspension period not to exceed 3 months; fee under 37. C.F.R. § 1.17(I) required).
- ☐ Other: _____

3. Fees

- ☒ RCE fee required under 37 C.F.R. §1.17(e) \$ 790.00
- ☒ Extension of time fee under 37 C.F.R. §1.17(a) \$ 120.00
- ☐ Other: _____ \$ _____

4. Method of Payment of Fees

- ☒ Enclosed is a check in the amount of: \$ 910.00
- ☐ Charge Deposit Account No. 13-2855 in the amount of: \$ _____
A copy of this transmittal is enclosed.


The Director is hereby authorized to charge any fee which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 01017/39555. A copy of this paper is enclosed.


Please direct all future communications to Marshall, Gerstein & Borun LLP at the address below.

Dated: August 10, 2005

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

By: 
Lynn L. Janulis
Registration No.: 53,066
Agent for Applicants
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to: Mail Stop RCE Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 10, 2005

Signature:

Lynn L. Janulis
(Lynn L. Janulis)

APPLICATION NO. 10/694,579
ATTORNEY DOCKET NO. 01017/39555

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Mehta <i>et al.</i>)	For: G-CSF Therapy as an Adjunct to
)	Reperfusion Therapy in the Treatment of
Application No: 10/694,579)	Acute Myocardial Infarction
)	
Filed: October 27, 2003)	Group Art Unit: 1647
)	
)	Examiner: James Jason Galvez

**AMENDMENT AND RESPONSE UNDER 37 C.F.R. §1.111 ACCOMPANYING
REQUEST FOR CONTINUING EXAMINATION UNDER 37 C.F.R. §1.114**

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This paper accompanies a Request for Continuing Examination (RCE) submitted herewith under 37 C.F.R. §1.114 and is in response to an Advisory Action mailed July 15, 2005. Please enter the amendment filed on May 20, 2005 along with the present amendment. Reconsideration and withdrawal of the rejections is respectfully solicited for the reasons set out in the amendment filed on May 20, 2005 along with present amendment. This response is timely filed as it is accompanied by a petition for an extension of time and the requisite fee.

Please amend the above-identified application as follows:

Amendments to the Specification: none.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.